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CASE REPORT 
Completion of Chronic Hepatitis C Virus Treatment in Interferon-
Induced Major Depressive Disorder with Psychotic Features 
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Assistant Professor of Clinical Pharmacy, Titus Family Department of Clinical Pharmacy and Pharmaceutical Economics & Policy, University of 
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Interferon (IFN)-associated psychiatric disorders can be managed without interruption to hepatitis C virus (HCV) treatment. The limited 
number of cases in the literature reporting psychotic depression as an adverse drug reaction to IFN resulted in discontinuation of HCV 
therapy. The author reports a case of a 49 year-old man with chronic HCV genotype 1a treated with pegylated interferon-alpha and riba-
virin developing major depressive disorder with psychotic features. The patient was successfully treated with both an antidepressant and 
antipsychotic for this suspected IFN-associated adverse drug effect while continuing 12 months of uninterrupted HCV treatment and sub-
sequently achieving sustained hepatitis C virological response. Although IFN can cause distressing psychiatric disturbances, appropriate 
treatment with psychotropic agents and careful monitoring allows patients to be maintained on a full course of HCV treatment. 
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INTRODUCTION
Standard pharmacologic treatment for chronic hepatitis C 
virus (HCV) infection for a disease that afflicts more than 170 
million people worldwide
1 is the antiviral combination of pe-
gylated interferon (IFN) and ribavirin (RBV).
2 IFN treatment 
is associated with psychiatric adverse drug reactions
3 such as 
major depressive disorder,
4,5 mania,
6 psychosis
7-9 and suicidal 
ideation.
10 Depending on its severity, discontinuation of IFN 
may be warranted.
7 If monitored closely and managed careful-
ly, however, patients with HCV can be placed on psychotropic 
medications to treat depressed mood, irritability, and even au-
ditory and visual hallucinations, whereby sustaining HCV 
treatment.
9 In the following report, an HCV-infected patient 
was treated with a full course of IFN and RBV while being as-
sessed regularly and adequately maintained on an antidepres-
sant and antipsychotic for emergent psychotic depression. The 
patient eventually achieved a sustained virological response 
(SVR) with a full course of uninterrupted HCV treatment due 
to control of psychiatric symptoms. 
CASE
A 49 year-old man diagnosed with chronic HCV genotype 
1a was screened at the hepatitis C clinic. He was been infected 
approximately 30 years ago from intravenous drug use which 
stopped 18 years ago. After starting a 48-week course of HCV 
therapy he progressively developed major depressive disorder 
(MDD) with psychotic features requiring pharmacologic in-
tervention. 
Laboratory findings prior to IFN initiation included an 
HCV RNA viral load of 2,950,000 copies/mL. Hepatitis B sur-
face antigen and HIV tests were both negative. Hematological 
findings were unremarkable and baseline TSH was 1.70 uIU/
mL (normal= 0.5-3.50). Routine depression monitoring on 
clinic visit 1 revealed a baseline Personal Health Question-
naire-9 items
11 (PHQ-9) score of 3, indicating decreased en-
ergy experienced almost daily. Table 1 summarizes depres-
sive symptoms over the course of IFN treatment, which 382  Psychiatry Investig 2011;8:381-383
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demonstrates a significant increase in the depression score 
when HCV treatment first began. Pegylated interferon-alpha 
180 micrograms once weekly and ribavirin 600 mg twice dai-
ly were started. Approximately seven weeks after initiation, the 
patient began reporting feelings of depressed mood, impaired 
sleep, poor concentration, and passive suicidal ideation (PHQ-
9 score of 19). He insisted, however, that he would never take 
his own life due to personal religious convictions. 
He was counseled about the possibility that his depression 
could get worse without an antidepressant and subsequently 
his HCV treatment may have to be discontinued. He there-
fore agreed to start citalopram. When the dose was eventually 
increased to 60 mg/day, his mood remained mildly depressed 
but he no longer reported anhedonia. He requested to be 
maintained on this maximum dose through week 29.
When the patient returned to clinic for routine follow-up at 
week 33, it was discovered that he was inadvertently taking a 
lower daily antidepressant dose of 40 mg for the past two and 
a half weeks. He started to report severe worsening of mood, 
passive suicidal ideation, impaired concentration, un-intru-
sive auditory and visual hallucinations, and mild paranoia 
around people he was unfamiliar with. Citalopram was im-
mediately increased back to 60 mg/day. The patient denied 
suicidality and the interdisciplinary team decided that hospi-
talization was not required. The clinician corroborated the re-
port with the patient’s sister and agreed to follow the patient 
more closely with home telephone calls. The patient agreed to 
start an antipsychotic and was maintained on aripiprazole 15 
mg/day. One week later, suicidal thinking was minimal and 
hallucinations were less bothersome but still present. Mild 
paranoid thinking persisted for 7 additional weeks until final-
ly subsiding.
The patient was able to complete the full 48-week course of 
IFN and RBV indicated for HCV genotype 1b without a de-
crease in IFN dose, interruption in therapy, or further com-
plications. When added to the HCV medications, both citalo-
pram and aripiprazole were well-tolerated. The PHQ-9 score 
by the end of treatment was 7, indicating that he had positive 
treatment response to the antidepressant. Although aripipra-
zole was discontinued, citalopram 40 mg/day for an addition-
al 6 months with a corresponding PHQ-9 score of 4 was con-
tinued. At the 1-year follow-up visit, the patient maintained an 
SVR and no longer required either psychotropic medication.
DISCUSSION
IFN-induced psychiatric complications are a common rea-
son for HCV treatment discontinuation. There are few reports 
describing patients who develop symptoms of clinical depres-
sion with psychosis occurring after the initiation of IFN and 
RBV therapy.
9,12,13 A case of MDD with psychotic features in-
duced by IFN in a polydrug user describes the patient requir-
Table 1. 48 weeks of hepatitis C virus treatment and co-occurring events
Time (weeks) Target symptoms/Response PHQ-9 score Psychotropic progression 
0 Decreased energy  3 None 
7 Decreased energy, depressed mood, impaired sleep, anhedonia,  
  worthlessness, mild anxiety, poor concentration, passive suicidal   
  ideation 
19 Citalopram 10 mg × 3 days, then increased to 
  20 mg/day thereafter 
12 Decreased energy, depressed mood, improved sleep, anhedonia,  
  poor concentration, less suicidal ideation 
11 Increased citalopram to 40 mg/day 
21 Decreased energy, improved mood but still depressed, increased  
  interest in usual daily activities  
10 Increased citalopram to 60 mg/day 
29 Euthymic mood, no longer passive suicidal thinking  NA Continue citalopram 60 mg/day 
33* Suicidal ideation, severely impaired concentration, increased  
  anxiety, active auditory and visual hallucinations 
25 Was unknowingly given a refill for only  
  citalopram 40 mg/day by a different clinician;   
  increased citalopram to 60 mg/day today 
34* Less suicidal, moderate anxiety, some residual auditory and  
  visual hallucinations; mild persistent paranoia
19 Start aripiprazole 5 mg × 7 days then increases 
  to 10 mg/day thereafter; Continue citalopram  
  60 mg/day 
38 Euthymic mood, fewer hallucinations; mild persistent paranoia   NA Increased aripiprazole 15 mg/day;  
  Continue citalopram 60 mg/day 
48 Euthymic mood, low energy; no paranoia 7 Decreased aripiprazole 10 mg/day;  
  Continue citalopram 60 mg/day 
Maximum score on the Personal Health Questionnaire (PHQ-9) is 27. *called patient at home twice between weeks 33 and 34. NA: not availableSH Park
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ing discontinuation of HCV treatment and the addition of an 
antidepressant and antipsychotic agent.
12 In other instances, 
patients do not require cessation of HCV treatment when such 
adverse psychiatric events occur as long as a psychotropic ag-
ent is implemented.
14 If feasible, concomitant treatment with 
appropriate psychotropics should be initiated with continu-
ous HCV treatment. Further studies are needed to address 
the appropriateness of stopping such agents relative to the end 
of HCV treatment. 
Possible neurochemical mechanisms of IFN-induced psy-
chopathology include diminished serotonergic neurotransmi-
ssion.
15 Hepatic tryptophan dioxygenase degrades trypto-
phan, the precursor of serotonin. This suggests that as a class 
of polypeptide cytokines, IFNs possess anti-serotonergic ef-
fects and may suppress serotonin synthesis. Further investiga-
tion is required to describe depression provocation by IFN.
Depressive symptoms, when inadequately controlled, can 
lead to secondary psychosis. The psychotic features in this pa-
tient were mood-congruent to the depression. Once the de-
pression eventually improved, the psychotic symptoms began 
remitting. Careful observation was required to ensure that he 
would not act upon the command auditory hallucinations and 
paranoia and subsequently harm himself. This required addi-
tional close contact with the patient’s sister in order to ensure 
completion of HCV treatment even in the presence of co-mor-
bid psychiatric complications caused by the antiviral medica-
tions.
Liver function tests monitoring continued and no compli-
cations or adverse events were observed with concomitant use 
of aripiprazole and citalopram. Once-daily aripiprazole was 
chosen because the patient did not wish to be overly sedated, 
as he was already feeling fatigue from IFN. A careful balance 
between minimizing psychotropic polypharmacy and ade-
quately managing substance-induced mood disorder should 
exist. This is the first reported case of aripiprazole used in the 
management of IFN-induced psychotic depression where 
HCV treatment completion resulted in SVR. There is a report 
on the use of aripiprazole 10 mg/day in a patient who devel-
oped IFN-induced psychosis with no noted depression who 
had to prematurely discontinue HCV treatments.
16
Clinicians should work together to manage adverse psychi-
atric drug reactions in order to sustain HCV-infected individ-
uals on necessary antiviral regimens with the goal of achiev-
ing SVR. Early detection and treatment of psychiatric compli-
cations induced by IFN can spare HCV treatment. Careful 
psychiatric symptom assessment of patients using IFN is re-
quired in all patients at baseline and as HCV treatment pro-
gresses. Immediate identification of serious adverse effects 
and intervention with appropriate psychotropic treatments 
allows patients to be managed for psychiatric side effects 
while being maintained successfully on the difficult treatment 
regimen for HCV. 
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